8 terminated. 8 Phase 2, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Terminated 8 |
| Phase 1 | 3 | Terminated 3 |
| Phase 3 | 2 | Terminated 2 |
Follow Muscle Spasticity: new trials by email Literature Review of Muscle Spasticity trials Research Report on Muscle Spasticity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity Phase 2; Low Dose MYOBLOC (10,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo - Spasticity, Cerebrovascular Accident | Phase 2 / Phase 3 | Terminated | Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC | 32 | 2021-11-02 | 2026-05-27 |
| Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity Phase 2; Low Dose MYOBLOC (15,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo - Spasticity | Phase 2 / Phase 3 | Terminated | Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC | 40 | 2019-12-17 | 2026-05-22 |
| Botulinum Toxin-A as a Treatment for Chronic Muscle-Related Pain in Adults With Spastic Cerebral Palsy: a Randomized Controlled Trial Dysport®, Normal saline - Pain, Cerebral Palsy, Spastic | Phase 2 | Terminated | Kristina Tedroff | 16 | 2015-08-01 | 2018-10-09 |
| One Year Extension Study To Protocol C2/5/TZ:MS-05 sublingual tizanidine 12 mg - Spasticity, Multiple Sclerosis | Phase 1 / Phase 2 | Terminated | Teva GTC | 10 | 2008-01-01 | 2009-02-19 |
| Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Due to Spinal Cord Injury tolperisone HCl (AV650), Placebo - Muscle Spasticity | Phase 2 | Terminated | Avigen | 120 | 2007-09-01 | 2008-11-04 |
| Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Associated With Multiple Sclerosis tolperisone HCl - Muscle Spasticity | Phase 2 | Terminated | Avigen | 150 | 2007-09-01 | 2008-11-04 |
| Cannabis for Spasticity in Multiple Sclerosis Inhaled Cannabis, Oral THC, Oral Placebo - Multiple Sclerosis | Phase 1 / Phase 2 | Terminated | University of California, Davis | 41 | 2004-04-14 | 2018-05-18 |
| Cannabis for Spasticity in Multiple Sclerosis Smoked Cannabis - Multiple Sclerosis | Phase 1 / Phase 2 | Terminated | Center for Medicinal Cannabis Research | 60 | 2003-03-01 | 2007-04-04 |
Multiple Sclerosis (5) · Brain Injuries, Traumatic (2) · Cerebral Palsy (2) · Hemiplegia (2) · Marijuana Abuse (2) · Stroke (2) · Fatigue (1) · Pain (1) · Spinal Cord Injuries (1)
Muscle Hypertonia (8) · Muscular Diseases (8) · Musculoskeletal Diseases (8) · Nervous System Diseases (8) · Neurologic Manifestations (8) · Neuromuscular Manifestations (8) · Pathological Conditions, Signs and Symptoms (8) · Signs and Symptoms (8) · Autoimmune Diseases (5) · Autoimmune Diseases of the Nervous System (5) · Demyelinating Autoimmune Diseases, CNS (5) · Demyelinating Diseases (5) · Immune System Diseases (5) · Central Nervous System Diseases (4) · Brain Diseases (3)
Clinical Trials, Phase II as Topic (2) · Clinical Trials, Phase III as Topic (2) · Tolperisone (2) · rimabotulinumtoxinB (2) · Dronabinol (1) · Saline Solution (1) · Sodium Chloride (1) · abobotulinumtoxinA (1) · nabiximols (1)
Avigen (2) · Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC (2) · Center for Medicinal Cannabis Research (1) · Kristina Tedroff (1) · Teva GTC (1) · University of California, Davis (1)
United States (5) · Hungary (2) · Poland (2) · Canada (1) · Czechia (1) · Germany (1) · Israel (1) · Russia (1) · Serbia (1) · Sweden (1) · Ukraine (1)
Joseph T Hull, PhD (2) · Arnon Karni, MD (1) · Glenn Morrison, MSc, PhD (1) · Kristina Tedroff, MD, PhD (1) · Mark Agius, M.D. (1) · Michelle Apperson, MD, PhD (1) · Ralph J Marino, MD (1)